MX390949B - Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer. - Google Patents
Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.Info
- Publication number
- MX390949B MX390949B MX2018000598A MX2018000598A MX390949B MX 390949 B MX390949 B MX 390949B MX 2018000598 A MX2018000598 A MX 2018000598A MX 2018000598 A MX2018000598 A MX 2018000598A MX 390949 B MX390949 B MX 390949B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- antibody fragments
- cancer treatment
- radiolabeled antibody
- emitter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nuclear Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193700P | 2015-07-17 | 2015-07-17 | |
| EP16153372 | 2016-01-29 | ||
| PCT/EP2016/066934 WO2017013026A1 (en) | 2015-07-17 | 2016-07-15 | Radiolabelled antibody fragments for use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000598A MX2018000598A (es) | 2018-05-11 |
| MX390949B true MX390949B (es) | 2025-03-21 |
Family
ID=57833837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000598A MX390949B (es) | 2015-07-17 | 2016-07-15 | Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11298433B2 (enExample) |
| EP (1) | EP3325020B1 (enExample) |
| JP (1) | JP6917357B2 (enExample) |
| KR (2) | KR20180042226A (enExample) |
| CN (1) | CN108025093B (enExample) |
| AU (1) | AU2016294858B2 (enExample) |
| CA (1) | CA2991398A1 (enExample) |
| MX (1) | MX390949B (enExample) |
| WO (1) | WO2017013026A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11517632B2 (en) * | 2017-06-20 | 2022-12-06 | Nanomab Technology Limited | Anti-Her2 single chain antibody and coding sequence and use thereof |
| EP3967674A1 (en) * | 2020-09-11 | 2022-03-16 | Precirix N.V. | Reactions of radioactive compounds facilitated by a solid phase |
| CN112561871B (zh) * | 2020-12-08 | 2021-09-03 | 中国医学科学院北京协和医院 | 一种基于平扫ct图像的主动脉夹层分割方法和装置 |
| KR20230159831A (ko) * | 2021-02-22 | 2023-11-22 | 압데라 테라퓨틱스 인크. | 표적화된 방사성 동위원소 요법을 위한 면역접합체 |
| CN119604536A (zh) * | 2022-05-23 | 2025-03-11 | 塞雷乌斯股份有限公司 | Her2结合剂及其用途 |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| CN116719074B (zh) * | 2023-05-29 | 2026-04-07 | 中国核电工程有限公司 | 一种两栖生物辐射剂量率的获取方法及装置 |
| WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
| WO2025195495A1 (zh) * | 2024-03-21 | 2025-09-25 | 启德医药科技（苏州）有限公司 | 一种放射性核素偶联物及其制备方法和用途 |
| WO2026008881A1 (en) | 2024-07-05 | 2026-01-08 | Synaffix B.V. | Extracellular vesicles comprising biomolecule-conjugates |
| US12600794B2 (en) | 2024-07-23 | 2026-04-14 | Abdera Therapeutics Inc. | 5T4 binding polypeptides and uses thereof |
| WO2026030445A1 (en) | 2024-07-30 | 2026-02-05 | Wisconsin Alumni Research Foundation | Degradation targeting agents and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| ATE370235T1 (de) | 1994-09-16 | 2007-09-15 | Cancer Res Fund Of Contra Cost | Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| JP2000515002A (ja) | 1996-06-27 | 2000-11-14 | フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 |
| WO1999037681A2 (en) | 1998-01-26 | 1999-07-29 | Unilever Plc | Method for producing antibody fragments |
| WO2000040968A1 (en) | 1999-01-05 | 2000-07-13 | Unilever Plc | Binding of antibody fragments to solid supports |
| AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
| CN1252264C (zh) | 1999-04-22 | 2006-04-19 | 荷兰联合利华有限公司 | 利用单价抗原－结合蛋白抑制病毒感染 |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| EP1242460B1 (en) | 1999-11-29 | 2006-10-18 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
| WO2001044301A1 (en) | 1999-11-29 | 2001-06-21 | Unilever Plc | Immobilized single domain antigen-binding molecules |
| EP1134231B1 (en) | 2000-03-14 | 2009-04-15 | Unilever N.V. | Antibody heavy chain variable domains against human dietary lipases, and their uses |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| ATE513854T1 (de) | 2000-12-13 | 2011-07-15 | Bac Ip B V | Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen |
| US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| JP4323317B2 (ja) | 2001-12-21 | 2009-09-02 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） | 可変領域配列のクローニング方法 |
| WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20090304590A1 (en) | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| WO2009068631A1 (en) * | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| US20110200525A1 (en) | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
| EP3495000A1 (en) * | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| AU2013201422B2 (en) | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| WO2014140376A1 (en) | 2013-03-15 | 2014-09-18 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases |
| WO2014198748A1 (en) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| WO2015073746A2 (en) | 2013-11-13 | 2015-05-21 | Whitehead Institute For Biomedical Research | 18f labeling of proteins using sortases |
| JP6289733B2 (ja) | 2014-07-29 | 2018-03-07 | フレイエ ユニヴェルシテイト ブリュッセルＶｒｉｊｅ Ｕｎｉｖｅｒｓｉｔｅｉｔ Ｂｒｕｓｓｅｌ | 癌の予防及び／又は治療に用いるための放射標識抗体断片 |
| US20180036442A1 (en) * | 2014-07-29 | 2018-02-08 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
-
2016
- 2016-07-15 WO PCT/EP2016/066934 patent/WO2017013026A1/en not_active Ceased
- 2016-07-15 MX MX2018000598A patent/MX390949B/es unknown
- 2016-07-15 KR KR1020187001952A patent/KR20180042226A/ko not_active Ceased
- 2016-07-15 US US15/742,161 patent/US11298433B2/en active Active
- 2016-07-15 EP EP16745643.3A patent/EP3325020B1/en active Active
- 2016-07-15 JP JP2018502118A patent/JP6917357B2/ja active Active
- 2016-07-15 CA CA2991398A patent/CA2991398A1/en active Pending
- 2016-07-15 KR KR1020257039216A patent/KR20250174696A/ko active Pending
- 2016-07-15 AU AU2016294858A patent/AU2016294858B2/en active Active
- 2016-07-15 CN CN201680053382.1A patent/CN108025093B/zh active Active
-
2022
- 2022-03-11 US US17/692,315 patent/US12440586B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018532689A (ja) | 2018-11-08 |
| CA2991398A1 (en) | 2017-01-26 |
| WO2017013026A1 (en) | 2017-01-26 |
| US12440586B2 (en) | 2025-10-14 |
| US20220323620A1 (en) | 2022-10-13 |
| BR112018000672A2 (pt) | 2018-09-18 |
| AU2016294858A1 (en) | 2018-02-01 |
| US20180200393A1 (en) | 2018-07-19 |
| EP3325020A1 (en) | 2018-05-30 |
| CN108025093B (zh) | 2022-02-11 |
| US11298433B2 (en) | 2022-04-12 |
| AU2016294858B2 (en) | 2022-08-11 |
| JP6917357B2 (ja) | 2021-08-11 |
| CN108025093A (zh) | 2018-05-11 |
| KR20180042226A (ko) | 2018-04-25 |
| EP3325020B1 (en) | 2022-01-12 |
| MX2018000598A (es) | 2018-05-11 |
| KR20250174696A (ko) | 2025-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| EA202090104A1 (ru) | Молекулы антител к cd73 и пути их применения | |
| MX2018000598A (es) | Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer. | |
| CL2021000353A1 (es) | Anticuerpo o fragmento de anticuerpo del mismo que comprende una región de unión que se une a un supresor del dominio vista, composición que lo comprende, su uso para tratar o prevenir el cáncer, ácido nucleico aislado, vector de expresión, célula hospedadora, método para producir dicho anticuerpo o fragmento del mismo, y artículo de fabricación (divisional de solicitud n° 01646-2016) | |
| CY1124730T1 (el) | Αντισωματα εναντι pd-1 και χρησεις αυτων | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| MX2024015844A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| ECSP19086810A (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| MX2017013613A (es) | Neoepitodos de cancer. | |
| CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
| CY1119510T1 (el) | Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| EA201990183A1 (ru) | Аденовирус, вооруженный биспецифичным активатором т-клеток (bite) | |
| MX2021001841A (es) | Anticuerpos anti-gdf15, composiciones y metodos de uso. | |
| MX2018013038A (es) | Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos. | |
| CR20200042A (es) | Anticuerpos anti-cd137 | |
| AR113429A1 (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t | |
| MX388015B (es) | Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer. | |
| EA201790834A1 (ru) | Молекулы антител к pd-l1 и их применение | |
| MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| MX2020010653A (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso. | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d |